Show simple item record

dc.contributor.authorSkoulidis, F.en
dc.contributor.authorDe Langen, A.en
dc.contributor.authorPaz-Ares, L. G.en
dc.contributor.authorMountzios, G. S.en
dc.contributor.authorCurioni-Fontecedro, A.en
dc.contributor.authorCouraud, S.en
dc.contributor.authorJanssens, A.en
dc.contributor.authorRocco, D.en
dc.contributor.authorOhashi, K.en
dc.contributor.authorVincent, M. D.en
dc.contributor.authorKang, J. H.en
dc.contributor.authorSchvartsman, G.en
dc.contributor.authorLindsay, Colin Ren
dc.contributor.authorO'Byrne, K. J.en
dc.contributor.authorDziadziuszko, R.en
dc.contributor.authorAndersen, J. A. L.en
dc.contributor.authorHindoyan, A.en
dc.contributor.authorWilmanski, T.en
dc.contributor.authorWang, Y.en
dc.contributor.authorSchuler, M. H.en
dc.date.accessioned2023-10-25T08:48:37Z
dc.date.available2023-10-25T08:48:37Z
dc.date.issued2023en
dc.identifier.citationSkoulidis F, De Langen A, Paz-Ares LG, Mountzios GS, Curioni-Fontecedro A, Couraud S, et al. Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003679.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.9008en
dc.identifier.urihttp://hdl.handle.net/10541/626655
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.9008en
dc.titleBiomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Texas MD Anderson Cancer Center, Houston, TXen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record